NovaBridge Biosciences (NBP) Common Equity (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Common Equity data on file, last reported at $230.9 million in Q4 2025.

• Quarterly Common Equity rose 14.8% year-over-year to $230.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $230.9 million (up 14.8% YoY) and the FY2025 annual result came in at $230.9 million, up 14.8% from the prior year.
• Common Equity improved to $230.9 million in Q4 2025 per NBP's latest filing, from $201.2 million in the prior quarter.
• Across five years, Common Equity topped out at $713.2 million in Q4 2021 and bottomed at $201.2 million in Q4 2024.
• The 5-year median for Common Equity is $238.6 million (2023), against an average of $358.6 million.
• The widest annual swing landed in 2022, when Common Equity slumped 42.63%; it then advanced 14.8% in 2025.
• Tracing NBP's Common Equity over 5 years: stood at $713.2 million in 2021, then tumbled by 42.63% to $409.1 million in 2022, then slumped by 41.68% to $238.6 million in 2023, then slipped by 15.7% to $201.2 million in 2024, then rose by 14.8% to $230.9 million in 2025.
• Per Business Quant, the three latest NBP Common Equity figures stand at $230.9 million (Q4 2025), $201.2 million (Q4 2024), and $238.6 million (Q4 2023).

Peer Comparison